Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Ann Rheum Dis. 2017 Oct 25;77(1):141–148. doi: 10.1136/annrheumdis-2017-211489

Fig. 3.

Fig. 3

Mutated and germline human anti-PAD4 antibodies are not polyreactive and have no cross-reactivity to citrullinated antigens. (A) The specificity of mutated and GL anti-PAD4 monoclonal antibodies against ssDNA, dsDNA, LPS, insulin or cardiolipin was addressed by ELISA. The assays were performed in duplicate using serial dilutions of monoclonal antibody (stock 6.8 μM) or human SLE serum as positive control. (B) Reactivity of SHM and GL anti-PAD4 monoclonal antibodies to cyclic citrullinated peptide 3 (CCP3) was addressed by ELISA. The assays were performed in duplicate.